Vesper Bio
CompanyDenmark
Vesper Bio develops one asset, in phase 2 (VES001 in frontotemporal dementia). Mostly small molecule acting on proteostasis and SORT1; based in Denmark.
- 1
- Asset
- Furthest stage
- Phase 2
- 1
- Trial
- 1
- Signal
Pipeline
1Brain-penetrant sortilin ligand
Phase 2, Small molecule, Proteostasis, SORT1, frontotemporal dementia
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials1
- People23
- Signals1
- Similar companies6